Facility Manager / Sr. Manager (Contract)

Facility Manager / Sr. Manager (Contract)

Reporting to the Senior Vice President, CMC, the contract Facility Manager will be responsible for the day-to-day management and operation of ALX Oncology’s South San Francisco office and laboratories. This role will oversee facility maintenance, workplace services, safety, security, permitting, vendors, and general office operations to ensure a safe, functional, and well-maintained workplace. The contract Facility Manager will work closely with employees, leadership, property management, vendors, landlords, local regulatory officials, and service providers and will collaborate cross-functionally with HR, IT, Finance, and Operations. The ideal candidate is proactive, detail-oriented, service-minded, and comfortable working independently in a fast-paced, small-company environment.

This is a 6 to 12-month contract assignment offering approximately 40 hours per week. The anticipated pay rate is approximately $50-$65 per hour, depending on skills and depth of experience.  This position requires onsite presence at ALX’s South San Francisco office Monday – Wednesday, as well as availability to be onsite as needed during the remainder of the workweek, and on weekends to support facility needs.

Given the nature of the role, the contract Facility Manager / Sr. Manager may also need to be onsite before normal business hours or after employees have left for the day to coordinate facility activities and respond to operational needs.

Qualified contractors should have experience that includes:

• Facilities, office operations, or workplace management experience, including responsibility for day-to-day building and workplace operations in a biotechnology or life sciences company.
• Managing facility-related vendors, service providers, local regulatory officials, and property management relationships, including maintaining facility documentation, service records, contracts, permits, and compliance-related files.
• Environmental Health & Safety (EH&S) programs and workplace safety practices, and ALX staff training, including supporting compliance with applicable federal, state, and local requirements.
• Office space planning, workstation setup, furniture moves, and related workplace projects, including office buildouts, relocations, and the coordination of lab equipment moves and calibration.
• Workplace services that ensure conference rooms, common areas, kitchens, employee workspaces, and other shared spaces are functional, well-maintained, and appropriately stocked.
• Building access, security badge systems, and visitor procedures, including coordinating access, workspace setup, and equipment needs associated with employee onboarding and offboarding.
• Identifying and implementing opportunities to improve facility operations, workplace services, and operational efficiency.

Physical Demands:

These demands are representative of the physical activities associated with the assignment.

• Regularly move throughout the office and building to oversee facility operations, inspect workspaces, and respond to workplace needs.
• Standing, walking, and sitting throughout the day, and using a computer for varying periods of time.
• Ability to bend, reach, stoop, and perform other physical activities associated with inspecting facilities, accessing equipment, and handling workplace supplies.
• Ability to safely use step stools or ladders as needed to access facility equipment, supplies, or building systems.
• Ability to occasionally lift and/or move up to 30 pounds and assist with moving office materials, supplies, or equipment as needed.

About ALX Oncology

ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.